EMA recommends authorisation of first veterinary vaccine using RNA technology
The EMA’s Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion recommending authorisation of Nobivac NXT HCPChFeLV, a self‑amplify…
Impact analysis · 60/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
The EMA’s Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion recommending authorisation of Nobivac NXT HCPChFeLV, a self‑amplifying RNA‑containing vaccine for cats covering five pathogens; the recommendation will now be sent to the European Commission for a legally binding decision.
Quantitative evidence
- 15 closed‑facility studies and one field study in 142 cats
- Immunity: 3 years for panleucopenia virus, 1 year for other four pathogens
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
This vaccine combines live attenuated strains for four pathogens with a self‑amplifying RNA platform for feline leukaemia virus, triggering immune responses starting one week post‑vaccination and conferring multi‑year protection.
Market context
This innovation could place the sponsor in a first‑mover position in RNA veterinary vaccines, addressing a multi‑pathogen feline market.
Legal and regulatory context
This is a CVMP recommendation under the EMA’s veterinary procedure and must now be forwarded to the European Commission for a legally binding authorisation across the EU.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- 09db370fa594c3b2ac5d1ff105225752fa008f1e599159a3ddcbe2d7ac049424
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-04-21T232528Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.